<DOC>
	<DOCNO>NCT00419367</DOCNO>
	<brief_summary>In effort allow patient continue access vorinostat outside base study , patient actively receive study medication discontinue study receive vorinostat via another method support SPONSOR ( e.g . Named Patient Program ( NPP ) ) . For institution allow receipt investigational therapy outside clinical trial , patient actively receive study medication continue meet eligibility transition extension phase study base study close . The extension phase begin soon protocol amendment implement .</brief_summary>
	<brief_title>Compassionate Use Vorinostat Treatment Patients With Advanced Cutaneous T-Cell Lymphoma ( 0683-042 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Advanced cutaneous Tcell lymphoma follow two systemic therapy Female participant must negative serum pregnancy test within 3 day first dose vorinostat Female participant must finish menopause , surgically sterilize , agree use 2 adequate barrier method contraception Male participant must agree use 2 adequate barrier method contraception To treat extension phase study participant must treat base study Protocol 042 Currently receive potential histone deacetylase ( HDAC ) inhibitor ( e.g . valproic acid ) Currently receive systemic therapy CTCL . Corticosteroids similar strength 20 mg prednisone daily permit Pregnant lactate Known allergy component study drug Eligible study vorinostat CTCL patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>